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Objectives:
• Be able to recognize characteristic symptoms of intermittent claudication
• Diagnose PAD on the basis of history, physical exam, and simple limb blood
pressure measurements
• Recognize the significance of peripheral artery disease as a marker for coronary
or cerebrovascular atherosclerosis
• Provide appropriate medical management of atherosclerosis risk factors—
including use of antiplatelet therapy to reduce risk of myocardial infarction, stroke
and death
• Manage symptoms of intermittent claudication with program of smoking
cessation, exercise, and medication
The diagnosis of intermittent claudication secondary to peripheral artery disease
(PAD) can often be made on the basis of history and physical examination. Additional
evaluation of PAD is multi-modal and the techniques used will vary depending on the
nature and severity of the patient's presenting problem. Most patients can be
appropriately managed without referral for specialized diagnostic services or
interventions.
Claudication
The incidence and prevalence of PAD increases with age. Claudication is the
most common symptom of lower extremity PAD with and estimated prevalence of
>350,000 in the US. About only 5% of patients with claudication will ever develop
critical (limb threatening) ischemia.
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Claudication is pain, aching or muscle fatigue occurring after the onset of exercise
(walking) and relieved by rest. The history is characteristic and reproducible, and the
history alone is enough for diagnosis in most cases. A complete physical examination is
indicated, however, to evaluate potentially important contributing factors that may impact
clinical management. Pulse palpation should be correlated with symptom severity and
location. Auscultation of bruits inay be helpful, as well.
Claudication is a marker for atherosclerotic cardiovascular disease. The 20-25%
five-year mortality of patients with claudication is significantly higher than comparable
populations without claudication. Patients with claudication frequently have significant
coronary or cerebrovascular disease, with a correlative incidence of myocardial infarction
or stroke. Patients with claudication should be evaluated for risk factors for
atherosclerosis, including hypertension, lipid abnormalities, and diabetes mellitus. The
following blood tests should be performed in all new patients presenting with PAD:
• Complete blood count
• Platelet count
• Fasting blood glucose or hemoglobin A,
• Creatinine
• Fasting lipid profile
• Urinalysis (for glycosuria/proteinuria)
In addition, for patients with and early age of onset, personal or family history of
thrombotic events, or a lack of common risk factors for atherosclerosis, the following
laboratory investigations are indicated:
• Hypercoagulability screen
• Homocysteine levels
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Unless contraindicated, patients with atherosclerotic disease should be on aspirin,
or other antiplatelet therapy. Management guidelines for PAD patients are summarized in
the accompanying table.
Ankle/Brachial Index
Objective findings can help confirm the diagnosis of hemodynamically significant
peripheral artery disease. Because of its simplicity, the ankle brachial index (measured
with continuous wave Doppler and pneumatic cuffs) remains a mainstay of screening for
PAD. The ankle/brachial index (ABI) is defined as:
ankle pressure (higher of the tibial artery pressures)
Ankle/Brachial Index (ABI) = brachial pressure (higher of the two arm pressures)
The ABI should be measured in both legs of all new patients with intermittent
claudication. The ABI is considered abnormal if it isE0.90, but a normal individual will
typically have an ABI of 1.0 to 1.10. (Though the normal mean blood pressure at the
ankle is equal to mean brachial pressure, the pressure waveforms are different. The
normal ankle systolic blood pressure—measured with the patient supine—is slightly
higher than the brachial artery systolic pressure.) Patients with moderately severe
intermittent claudication typically have an ABI in the range of 0.70 to 0.90. The lower the
ABI, the more severe the disease. Patients with critical ischemia often have an ABI<0.35.
Treadmill Exercise Testing
Treadmill testing is sometimes useful in the evaluation of patients with
claudication. Treadmill tests can be conducted in a variety of ways, but usually the speed
is kept constant, for example, 2 mi/h (3.2 km/h). Either a fixed incline can be used, or a
graded intensity test profile can be selected.
David L. Dawson, MD	 3
The time or distance walked until the onset of claudication symptoms should be
recorded. This is the "pain free walking distance" (PFD) or the "initial claudication
distance" (ICD). When claudication symptoms stop the patient from walking any farther,
the patient has reached the "maximum walking distance" (MWD) or "absolute
claudication distance" (ICD). Pain is subjective and results for some patients may be
markedly different from others with similar severity of occlusive disease. Also, a
variability of ± 20% is not uncommon if the tests are repeated for a single patient on
different days.
Treadmill walking distances can be compared before and after therapy to evaluate
the efficacy of the intervention.
Treadmill walking tests are also useful for objectively documenting the severity
of, or confirming a diagnosis of claudication. A post-exercise drop in the ankle pressure
of •20 mm Hg is to be expected when patient's symptoms are truly from vasculogenic
claudication. A greater pressure drop, and a longer recovery time, indicates more severe
disease.
Some patients may have both mild to moderate PAD and musculoskeletal or
neurospinal conditions. If they develop symptoms that stop their walking early, but they
do not have an associated drop in ankle pressure; it is unlikely that vascular disease is the
exercise-limiting condition.
Treadmill tests can also be useful to document mild to moderate proximal
occlusive disease that only becomes hemodynamically significant under conditions of
exercise. Some patients with aortoiliac disease may have intact pulses and near normal
resting segmental pressures. However, after exercising on the treadmill a drop in the
limb pressures will be detectable.
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Peripheral Arterial Duplex Scanning
If it is desirable to localize and gauge the severity of the PAD in order to assist
with the planning of an intervention, duplex scanning or magnetic resonance
arteriography can be used as a preliminary, noninvasive examination before
arteriography. Arteriography is only indicated when a decision has already been made to
intervene, should a suitable lesion or pattern of disease be identified.
An experienced vascular sonographer can image the lower extremity arterial tree
from the diaphragm to the feet. While some studies can be limited by abnormal or
distorted anatomy (obesity, bowel gas, open wounds, etc.), most patients can be
successfully studied with ultrasound. Complete arterial mapping can take two hours or
more, though. Ultrasound B-mode imaging reliably demonstrates aneurysms,
pseudoaneurysms, and other morphologic features. Color flow imaging facilitates vessel
identification (especially useful when scanning small or deeply situated vessels). Color
flow imaging and pulsed Doppler can demonstrate patency, focal stenosis, and can
characterize segmental hemodynamics, but overall accuracy is better for larger, proximal
segments.' Further, the ability to specifically characterize degree of arterial narrowing
with duplex scanning is limited when there is significant proximal disease and when the
segment of interest has diffuse, rather than focal narrowing. Severe stenoses are generally
characterized by focal increases in velocity, but this may not be seen if the stenosis is not
well localized.
Office-based management of PAD
Claudication can significantly effect the quality of life of affected individuals. The
first line of therapy is a program of regular exercise and smoking cessation.
Pharmacologic treatment options include pentoxiphylline (Trental®) or cilostazol
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(Pletal ft but in a prospective, blinded comparison trial, cilostazol improved walking
ability more than either pentoxifylline or placebo. For patients with lifestyle limiting
symptoms that are not adequately managed with these means, surgical or endovascular
revascularization could be considered.
Additional Reading:
Dormandy J, Rutherford R. Management of peripheral arterial disease (PAD). TASC
Working Group. J Vasc Surg. 2000;31:S 1-S296.
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Medical Management Guidelines for
Peripheral Arterial Disease (PAD) Patients*
Goals Therapy Comments
Antiplatelet therapy Aspirin (ASA) I risk of MIt , stroke,
vascular death2, 3Clopidogrel (Plavix®)
ASA may reduce need for
surgery for PAD4
Clopidogrel may be more
effective for risk reduction
for PAD patients5
Management of specific atherosclerosis risk factors:
Cigarette smoking Behavioral programs risk of PAD progression,
MI, stroke, death6, 7Nicotine replacement
I risk of critical ischemiaBupropion (Wellbutrin®)
and limb loss8
Obesity Dietary modification
Tphysical activity
Diabetes mellitus Dietary therapy Intensive glycemic control
may improve outcomes,
Oral hypoglycemics; Metformin including I risk of MI and
(GlucophageO) and others death9-11
Insulin Recommend fasting blood
glucose 80 to 120 mg/dL;
postprandial glucose <180
mg/dL; hemoglobin
At,<7.0%
Adapted from the recommendations of the TransAtlantic Inter-society Consensus I
'MI: myocardial infarction
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Hyperlipidemia Screen all PAD patients Lp(a) in an independent risk
factor for PAD] 2
Dietary modification
PAD may stabilize or
Medications if LDL-cholesterol
regress with therapy 13-17
>_ 100 mg/dL
I risk of PADConsider niacin for low HDL-
progression 18cholesterol
Consider fibrates for low HDL- I risk of MI and
cholesterol and high cardiovascular death 19-21
triglycerides
Hypertension Manage according to guidelines Correlation to PAD
from Joint National Committee progression not established
(VI), National Heart, Lung, and
Blood Institute Marked I in systolic
pressure may slightly
worsen claudication
symptoms22
No contraindication to (3-
blocker use23
ACE inhibitor (ramipril,
Altace®) may I risk of MI
or death in PAD patients24
Hypercoagulable states Warfarin (Coumadin®)
Hyperhomocysteinemia Folic acid Elevated plasma
homocysteine is important
Vitamin B 12 PAD risk factor in patients
<50 years25Vitamin B6
Treatment I risks of
cardiovascular events and
death26, 27
Post-menopausal state Hormone replacement therapy May I risk of
(estrogen and progesterone) cardiovascular events in
women28
x ACE: angiotensin converting enzyme
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Pharmacotherapy for Symptoms of Intermittent Claudication
FDA approved drugs (recommended options)
Cilostazol
Pentoxifylline
Other established drugs with some or potential benefit for claudication
Buflomedil
Naftidrofuryl
Therapies with minimal or no benefit (not recommended for clinical use)
Antiplatelet drugs
Aminophylline
Anticoagulation
Cinnarizine
Defibrotide
Dextran
Ginkgo biloba
Isosuprine
Isovolemic hemodilution
Ketanserin
Nicotinic acid derivatives
Vasodilators
Verapamil (and other calcium channel blockers)
Vitamin E
Incompletely studied drugs with potential benefit (not yet FDA-approved)
Beraprost sodium
Carnitine
L-arginine
Propionyl-L-carnitine
Prostaglandins and prostanoids
Protein kinase C inhibitors
Vascular endothelial growth factor (VEGF)
' Adapted from recommendations of the TransAtlantic Inter-Society Consensus, reported by Dormandy J,
Rutherford R. Management of peripheral arterial disease (PAD). TASC Working Group. J Vasc Surg.
2000;3 I: S 1-S 296.
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FDA: United States Food and Drug Administration
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Treatment Algorithm for Patients with Peripheral Artery Disease
Initial Diagnostic Assessment
• Patient history: "Do you have pain, aching, or fatigue in your leg muscles
when you walk that disappears when you rest?"
• Physical examination: Include pulse evaluation & ankle-brachial index (ABI)
• Optional assessments: Treadmill test, Walking Impairment Questionnaire
PAD-Specific Lifestyle Modifications (See table)
• Begin lifelong antiplatelet therapy
• Control other atherosclerosis risk factors
• Walking exercise program, supervised whenever possible
modified from Dawson DL,
Chow MSS, Regensteiner
JG, Vogt MT, Hegg C, Lee
S, Treat-Jacobson D, Hirsch
AT: Treating intermittent
claudication secondary to
peripheral arterial disease.
Pharm Therap Dec 1999;
24(12): 616-622.
Critical ischemia
(rest pain or tissue loss)
11
	 Refer to vascular specialist	 11
I	 Intermittent claudication	 I
Lifestvle limiting discomfort
Consider drug therapy
Any contraindications to drug therapy?
I	 Mild claudication or	 I
asymptomatic
II No drug treatment needed for
claudication svmotoms
Yes I
	 I No
Re-evaluate periodically
Set reasonable and clearly-defined expectations
Re-evaluate patient in 90 days (office visit)
• Monitor response to therapy: treadmill test, walking
questionnaire, patient opinion
• Assess compliance, possible drug side effects
Is therapy effective? Patient willing to continue therapy?
No I
	
I Yes
Re-evaluate patient in 90 days
• Re-assess compliance, efficacy,' safety, and drug tolerance
I	 Benefit seen?	 I
Vascular
Specialist
Evaluation
Abbreviations: ICD = initial claudication distance; ACID = absolute claudication distance.
The efficacy of any claudication intervention can be assessed by use of the patient
history, or more formal use of walking impairment questionnaires, treadmill tests, or
objective quality of life evaluations.
No I
	
I Yes
Continue therapy
Re-evaluate periodically
